On March 8, 2022 Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, reported the publication of two abstracts for its upcoming poster presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (Press release, Cogent Biosciences, MAR 8, 2022, View Source [SID1234609676]). The meeting will be hosted April 8-13, 2022 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The first poster presentation will highlight new nonclinical data on the unique properties of bezuclastinib that differentiate it from other KIT inhibitors. Bezuclastinib is currently under clinical investigation in Advanced Systemic Mastocytosis (NCT04996875), Nonadvanced Systemic Mastocytosis (NCT05186753), and imatinib-resistant Gastrointestinal Stromal Tumors (GIST) (NCT05208047). A second poster presentation will reveal in vitro and in vivo characteristics of a novel series of FGFR inhibitors with potency against clinically relevant mutations.

Details for the poster presentations are as follows:

Abstract Number: 147
Title: Bezuclastinib is a differentiated KIT inhibitor that exhibits unique selectivity to KIT A-loop mutations, minimal brain penetration, and favorable pharmacokinetic properties in preclinical models
Session Category: Molecular/Cellular Biology and Genetics
Session Title: Kinases and Phosphatases
Session Date and Time: Sunday, April 10, 2022, 1:30 – 5:00PM CT
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 8

Abstract Number: 167
Title: Pre-clinical characterization of a novel series of FGFR2 selective inhibitors with potency against clinically relevant mutations
Session Category: Molecular/Cellular Biology and Genetics
Session Title: Kinases and Phosphatases
Session Date and Time: Sunday, April 10, 2022, 1:30 – 5:00PM CT
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 8